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Abstract
Background—The aim of this study was to describe the impacts of inflammatory bowel disease
(IBD) from the patients’ perspective, and to inform the development of a conceptual model.
Methods—Focus groups and one-on-one interviews were undertaken in adult patients with IBD.
Transcripts from the focus groups and interviews were analyzed to identify themes and links
between themes, assisted by qualitative data software MaxQDA. Themes from the qualitative
research were supplemented with those reported in the literature and concepts included in IBD-
specific patient-reported outcome (PRO) measures.
Results—Twenty-seven patients participated. Key physical symptoms included pain, bowel-
related symptoms such as frequency, urgency, incontinence, diarrhea, passing blood, and systemic
symptoms such as weight loss and fatigue. Participants described continuing and variable
symptom experiences. IBD symptoms caused immediate disruption of activities but also had
ongoing impacts on daily activities, including dietary restrictions, lifestyle changes, and
maintaining close proximity to a toilet. More distal impacts included interference with work,
school, parenting, social and leisure activities, relationships, and psychological well-being. The
inconvenience of rectal medications, refrigerated biologics, and medication refills emerged as
novel burdens not identified in existing PRO measures.
Conclusions—IBD symptoms cause immediate disruption in activities, but patients may
continue to experience some symptoms on a chronic basis. The conceptual model presented here
may be useful for identifying target concepts for measurement in future studies in IBD.
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INTRODUCTION
The chronic nature of Inflammatory Bowel Disease (IBD) leads to a significant impact on
patients’ lives, beyond intestinal symptoms alone. The sequelae of this can be seen in the
increased rates of depression, and reduced workforce participation reported in patients with
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ulcerative colitis (UC) or Crohn’s disease (CD) 1,2,3. In addition, the necessity for chronic
medical therapies to maintain clinical remission of the disease generates its own obstacles
for patients 4,5.
Several patient-reported outcome (PRO) measures have been developed for IBD with the
goal of quantifying the holistic effects of these conditions. These PROs focus on the health-
related quality of life impacts of this condition 6,7,8 but they each differ widely in content
and, overall, lack coverage with respect to some important concepts9. Although IBD
presents a substantial burden to patients’ lives, a conceptual model that fully describes the
respective disease impacts has not yet been developed. Conceptual models characterize
proximal and more distal impacts of a condition and the inter-relationships among them.
These models provide a comprehensive picture of the burden of disease and can be used to
identify areas in which treatment benefits may be observed. The objective of this study was
to understand IBD and its treatment from the patient perspective to help inform a
comprehensive conceptual model of IBD impacts.
METHODS
This was a qualitative study in which focus groups and one-on-one interviews were
conducted with adults with ulcerative colitis or Crohn’s disease to identify the impacts of
IBD and its management, excluding surgery. To ensure comprehensive coverage, a review
of published studies that included focus groups or qualitative interviews with IBD patients,
and a content analysis of IBD-specific PRO measures, were also performed.
Qualitative research with patients
Participants were recruited through a tertiary clinical site specializing in the treatment of
IBD. Patients were eligible if they were 18 years of age or older, had mild or moderate UC
or CD at the time of interviews, and were currently prescribed mesalamine for maintenance
of their IBD. Using a standardized moderator guide, a trained interviewer asked open-ended
questions to elicit patients’ experiences of living with IBD, and to rate their IBD on a 0-10
bothersome scale, where 0=not at all bothersome and 10=extremely bothersome. Data were
collected until information saturation was attained, i.e., until no new information was being
identified. The focus groups and interviews were convened at the Beth Deaconess Medical
Center, Boston, MA, where full Institutional Review Board approval was obtained.
Literature Review
A review of the literature in Medline, EMBASE, and PsychINFO databases was performed
to identify qualitative research articles in adult patients with IBD, either UC and/or CD, with
search terms that included ‘patient perspective,’ ‘qualitative,’ ‘focus group,’ and
‘interviews.’ There were no date restrictions. In addition, PRO measures that were
developed to assess health-related quality of life impacts in patients with IBD were
reviewed. In order to capture the impact of IBD managed medically, articles or PRO
measures that focused solely on the impacts of surgery were excluded.
Analyses
Transcripts from the focus groups and one-on-one interviews were analyzed following the
principles of Grounded Theory10 to identify themes and possible links between themes.
Qualitative data analysis software MaxQDA (version 10.0) was used to code and facilitate
organization of the data. In accordance with standard qualitative data analysis, a saturation
table was constructed to assess data saturation 11. Themes that emerged from the qualitative
research were compared with concepts reported in the literature and items in IBD-specific
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PRO measures to inform the development of a comprehensive conceptual model on the
impacts of IBD and its treatment.
RESULTS
Twenty-seven patients (4 focus groups comprising 2-6 participants each and 10 one-on-one
interviews) participated. The mean age was 31.5 years (range; 20-59), 52% (n=14) were
male, and 78% (n=21) had UC, while 22% (n=6) had CD (Table 1). At the time of the
interviews, 21/27 were in clinical remission (based on Simple Colitis Clinical Activity Index
<2) but this was a disease-experienced cohort; the mean disease duration was 7 years, and
13/27 were also on maintenance immunomodulators or biologics due to prior moderate-
severe disease. The focus groups were conducted prior to the individual interviews, and the
evaluation of information saturation indicated that no new codes (themes) were added after
the eighth one-on-one interview, demonstrating data saturation. A comparison of themes did
not identify any differences in impacts between UC and CD patients.
Patient-Reported Burden of IBD
The key concepts associated with the burden of IBD identified by participants interviewed in
this study are highlighted in Table 2. These included physical symptoms of disease, resulting
in immediate impaired functioning, and broader impacts on lifestyle, daily activities
(including work, school, and parenting), social and leisure activities, relationships, and
psychological well-being. Example quotes from participants in the focus groups/interviews
are provided to illustrate concepts (Supplementary Table 1). Notable findings from each
theme are described below;
Symptom Patterns—Even during periods of ‘remission,’ participants reported symptoms
that fluctuated in severity from day to day. Although participants used the terms ‘flares’ and
‘remission,’ they described highly variable symptom experiences in these 2 states indicating
some overlap. For example, participants described ‘bad’ or ‘gigantic’ flares that were
associated with very severe symptoms, but they also reported ‘mild flares,’ or having ‘the
beginnings’ of a flare which they curtailed by resting, altering medications, using an enema,
or adding other medications. None of these were classified by the participant as an actual
flare. Participants emphasized that, even during remission, their bowel habits would not
generally be considered ‘normal’ by the general public. When asked about how bothersome
their IBD is (on a 0-10 scale), participants typically reported a 10 (range 8-10) during a
flare, but still gave ratings of 2-6 for how they typically feel, when not experiencing a flare,
depending on what they eat, concerns about ‘having it in the background’ and not being able
to plan ahead not knowing how they will feel.
Impact on Lifestyle—We identified 4 key impacts on lifestyle; taking medication,
restricting diet, modifying behaviors that triggered symptoms, and maintaining close
proximity to toilets. These, in turn, had significant other impacts on patients’ functioning.
Although an effective medication permitted them more freedom in food choices, participants
still reported the need to be careful in avoiding certain trigger foods. Despite their efforts,
not all participants successfully identified ‘triggers.’ Participants reported that despite doing
everything ‘right,’ they might still experience a flare, and this resulted in discouragement
and frustration.
Impacts on Daily Activities—Participants reported absences from work or school during
a flare due to pain, fatigue, and frequency. The likelihood of flares or dealing with recurrent
symptoms also impacted patients’ career plans. Participants also reported trying to manage
work stresses more effectively in order to prevent escalation of symptoms. Interview
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participants reported having to cancel trips or events if their symptoms unexpectedly
worsened. The unpredictability of their symptoms resulted in difficulty in planning ahead
and, in everyday life, they often avoided certain activities, such as camping and travel, or
reported that their social life was restricted by the need to maintain close proximity to toilets
or because of dietary restrictions.
Impacts on Relationships—While partners, family, and friends are generally perceived
to be supportive, some participants described others as lacking in understanding. Participants
reported that it was difficult to disclose their IBD to new friends or a potential partner; a
‘major hurdle to overcome’ because of the nature of the disease.
Psychological impacts—Coming to terms with having a chronic, lifelong illness was
reported to be a challenge, particularly in a relatively young population. Participants
reported being acutely embarrassed by their IBD symptoms and humiliated if they had
fouled themselves in public. They reported being self-conscious about taking their
medication in social settings or what others thought on seeing the number of pills required.
This was especially difficult for young adults. Fears of having a flare and being incontinent
were highly prominent among participants. Participants expressed additional fears and
concerns regarding their disease and treatments. Disease-related concerns included those
related to the future course of their disease, possible shortened lifespan, and the risk of
developing cancer.
Treatment Impacts—Taking medication itself resulted in a number of impacts, including
side effects, the need to try several medications before identifying an effective treatment,
embarrassment, inconvenience, and financial burden. Regimens that require more than one
dose per day, and particularly those that required a mid-day dose, were reported to be more
burdensome. For many, the goal was to reduce doses to the minimum necessary to control
symptoms.
Treatment-related concerns included those about possible long-term effects of their current
treatments, worry that their current treatment would cease to be effective, concerns
regarding the availability of other treatment options, and the need to progress to more
‘serious’ medications or to surgery. Participants wanting to start a family or have additional
children were concerned about their disease or medications affecting their pregnancy and of
the possibility of passing on IBD to their offspring.
Development of Conceptual Model
The literature search of qualitative research articles in IBD yielded 454 abstracts. Within
these, 28 articles discussing patient-reported impacts of IBD were identified for full-text
review, of which 21 had convened focus groups or one-on-one interviews and thus were
included in this evaluation12-32. Additional details from these studies are provided to
supplement the descriptions of concepts elicited from study participants (Table 2). The 6
most widely used and established IBD-specific health-related quality of life measures9 were
reviewed: the Inflammatory Bowel Disease (IBDQ)6Questionnaire, a 36-item version of the
IBDQ 33, the Crohn’s Disease Perceived Work Disability Questionnaire(CDPWDG)34, the
Inflammatory Bowel Disease Stress Index (IBDSI)8, the Rating Form of IBD Patient
Concerns (RFIPC7, and the Work Productivity and Activity Impairment Questionnaire:
Crohn’s Disease (WPAI-CD) 35. Concepts captured by items in the IBD-specific PRO
measures were added to those identified by the focus groups, interviews, and qualitative
studies in the literature to produce an inventory of all concepts identified by each of these 3
sources. As can be seen from Table 2, some novel burdens of disease were identified by this
study, which do not appear in existing PROs. These data informed the development of a
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conceptual model of disease and treatment impacts (Figure 1). In this model, each arrow
indicates the direction of influence. For example, one arrow from treatment impacts
indicates that these have psychological impacts on patients, while a second arrow leading up
to lifestyle impacts illustrates that the impacts of treatment influence patients taking their
medication.
DISCUSSION
This research presents a comprehensive inventory of the key symptoms and impacts of IBD
from both qualitative research with patients as well as the literature. This study supports and
expands on themes reported in the literature and captured by PRO measures developed for
use in IBD. A notable addition is the presentation of the impacts of IBD treatments. There
have been a number of studies in this population but, to our knowledge, this is the first
attempt to consolidate the findings from all of these to provide a fully comprehensive picture
of the burden of IBD.
The symptoms of IBD include both gastrointestinal and systemic symptoms, which disrupt
immediate activities and cause embarrassment and worry to patients. These immediate
impacts result in a cascade of effects on a patient’s life and psychological well-being.
Symptoms and impacts are particularly severe during flares and as flares can occur more
than once a year36, presenting a significant burden. However, even during remission,
patients may not be entirely symptom-free and the overlap in symptoms between flare and
remission states is supported by reports in the literature29,37. Even when symptoms appear to
have completely remitted, it may be several months before patients feel sufficiently secure
that their symptoms are truly under control so that they regain confidence to engage in
normal activities28. Current findings, supported by the literature, illustrate the ongoing
impacts of living with IBD even when not experiencing an episode typically referred to as a
flare27.
With no available cure, IBD is managed by medication and changes in lifestyle, which
include changes in diet, reducing stress38 and ensuring sufficient sleep in order to minimize
the likelihood of worsening symptoms or initiating a flare. Patients report the need, or
perceived need, always to maintain proximity to a toilet in case of an urgent need to
defecate. These changes in turn, have further direct and indirect impacts on work/school/
home and parenting, social and leisure activities, relationships and psychological well-being,
as illustrated in the conceptual model.
IBD has significant psychological impacts due to fluctuating daily symptoms and the
unpredictability of exacerbations or flares, embarrassment and stigma of IBD symptoms,
fears related to long-term effects of treatments, treatment effectiveness, and progression of
disease which can cause anxiety, depression, and other emotional effects38. Although no
cognitive impairments were identified in the current focus groups or interviews, these are
evident in the literature31 and there are items enquiring about difficulties in memory,
concentration, and decision-making in IBD-specific PRO measures8). The burden of taking
IBD medications and patients’ negative perceptions of these treatments can adversely affect
treatment adherence, with consequences for disease management. To our knowledge, the
immediate impacts of treatment for IBD have previously not been fully addressed or
captured in the existing PRO measures.
The findings suggest no substantial differences between UC and CD with respect to
symptoms and impacts, in line with other studies which report many more similarities than
differences when comparing results by IBD diagnosis39,40,41 but further evaluation of the
model comparing UC and CD would be beneficial.
Devlen et al. Page 5
Inflamm Bowel Dis. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Strengths and limitations of the research, however, need to be taken into account when
drawing conclusions from the findings. The qualitative research involved 2 modes of data
collection, focus groups and interviews, thus minimizing any potential limitations that may
exist with either of these methods. Despite demonstrating information saturation within the
data collected, the sample size was small and there are likely biases in the patients sampled
for the qualitative research; these are limitations of the study. Furthermore, the PROs
identified for review are the most widely used, but there may be other, lesser-known
measures that include concepts not currently identified. Finally, we have not yet validated
the conceptual model in a novel cohort of patients.
The results of a recent review of IBD-specific measures suggested some important areas
may be missing9. By supplementing the content of PRO measures with findings from
qualitative research, in this study we have been able to identify and add specific concepts,
otherwise missing, to ensure greater coverage. Despite extensive coverage in development,
we recommend further evaluation of the comprehensiveness of the concepts and their
interactions described in the proposed model. Furthermore, the objectives were to capture
the impacts of IBD in adults managed medically and so the impacts on children and the
specific difficulties in having an ostomy bag after surgery are not included in this model.
CONCLUSIONS
This is the first study to present a comprehensive conceptual model of the impacts of IBD.
The conceptual model resulting from this study illustrates IBD symptoms and impacts and
the inter-relationships among them, capturing both acute and long-term impacts. Drawing
from multiple sources it provides a more comprehensive model than previously available
and helps to portray the full burden of IBD, including the impact of IBD treatments, from
the patient perspective. The conceptual model presented here may be useful for identifying
target concepts for measurement in future studies in IBD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Conceptual Model of Impacts of Inflammatory Bowel Disease
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Table 1
Participant Characteristics
Characteristic N=27
Age (years)
 Mean ± SD 31.5 ± 9
 Min, Max 20, 59
Gender
 Male 14 (52%)
 Female 13 (48%)
Disease duration (years)
 Mean ± SD 6.5 ± 6
 Min, Max 1, 20
Prior intestinal surgery 1 (4%)
Diagnosis
 Ulcerative Colitis 21 (78%)
 Crohn’s Disease 6 (22%)
Currently in clinical remission 21 (78%)
Current maintenance medication
 Asacol ® 12 (44%)
 Lialda ® 11 (41%)
 Pentasa ® 4 (15%)
Mesalamine schedule
 Once-a-day 15 (55%)
 Twice-a-day 9 (33%)
 Three times-a-day 3 (12%)
Concomitant immunomodulators 13 (48%)
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Table 2
IBD impacts reported by study participants, in literature, and IBD-specific PRO measures
Concept Reported by Participants Reported in Literature(12-32) Item in IBD-specific
PROa
Immediate Impacts
Disrupted activities X X CDPWDG, IBDQ,
IBDQ-36, IBDSI, RFIPC,
WPAI-CD
Embarrassment, worry, fear X X CDPWDG, IBDQ,
IBDQ-36, IBDSI, RFIPC,
Hospitalization X X
Lifestyle Impacts
Take medication X X
Restrict diet X X
Modify behaviors (eg, sleep, stress) X X
Maintain close proximity to toilet X X
Take precautions against incontinence (eg, using
pads such as ‘Depend products’)
X
Impacts on Daily Activities IBDSI
Absence from school/work X X CDPWDG, IBDQ,
IBDQ-36, IBDSI, WPAI-
CD
Impaired work performance X IBDSI, WPAI-CD
 • due to symptoms X X CDPWDG, IBDQ-36
 • due to medication or side effects X CDPWDG, WPAI-CD
 • due to lack of/difficulty accessing toilet X X CDPWDG
Problems at work due to IBD X X CDPWDG
Disability/ loss of job due to IBD X CDPWDG
Change job/ career /delay in education X X RFIPC
Difficulty with household tasks X WPAI-CD
Difficulties in role as parent X
Disturbed sleep X IBDQ, IBDQ-36, IBDSI
Impacts on Social and Leisure Activities
Delay or cancel activity X X IBDQ, IBDQ-36
Difficulty planning in advance X X
Avoiding events X X IBDQ, IBDSI
Restricted participation in events X IBDQ, IBDQ-36
 • due to lack of toilet facilities X X IBDQ-36
 • due to food restrictions X
Participating in activities associated with disease
relapse (eg, drinking alcohol, eating restricted
foods)
X X
Impacts on Relationships X IBDQ-36, IBDSI
Alienation from family and friends X X
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Concept Reported by Participants Reported in Literature(12-32) Item in IBD-specific
PROa
Being a dependent/burden on others X X RFIPC
Perceived lack of understanding/support X IBDQ
Withdraw from dating X X
Difficulties with intimacy X X RFIPC
Limited sexual activity X IBDQ, IBDQ-36, IBDSI
Break-up/divorce X
Treatment Impacts
Side effects X X RFIPC
Difficulty finding effective treatment X X
Pill burden
 • reluctance to take any medication X X
 • pill characteristics X X
 • number/timing of doses X X
 • reminder of illness X X
Inconvenience
 • applying rectal medications X
 • need to refrigerate medications X
 • carrying medications X X
 • refilling prescriptions X
 • visits to physician/hospital X X
Financial burden X X
Psychological Impacts
Feelings of loss of control X X IBDSI, RFIPC
 • unpredictability of daily symptoms X X
 • unpredictability of flare X X
Altered self concept IBDSI
 • change in body image X RFIPC
 • loss of attractiveness X X IBDSI
 • difficulty in identity as chronically ill X X
 • adapting to new bowel habits X X
 • lowered self esteem X IBDSI
Embarrassment/Stigma/Humiliation IBDQ, IBDSI
 • symptoms of IBD (eg, incontinence, noises,
flatulence)
X X IBDQ-36
 • feeling dirty, smelly X IBDSI, RFIPC
 • being treated as different RFIPC
 • taking medication, many pills X X
 • need to hide IBD, pills at work X X CDPWDG
Fear/worry IBDSI
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Concept Reported by Participants Reported in Literature(12-32) Item in IBD-specific
PROa
 • being incontinent X X IBDQ
 • having a flare X X IBDQ, IBDQ-36
 • side effects/long term effects of medications X X RFIPC
 • never feeling better IBDQ, IBDQ-36
 • treatment will cease to be effective X X
 • future treatment options X X
 • disease progression X X IBDQ
 • need for surgery X X IBDQ, IBDQ-36
 • need for stoma/ostomy X X
 • developing cancer X X IBDQ, IBDQ-36
 • death/shortened lifespan RFIPC
 • fertility/pregnancy X X RFIPC
 • passing IBD to offspring X IBDQ-36, RFIPC
Emotional Impacts IBDQ-36
 • frustrated/discouraged X X IBDQ, IBDQ-36
 • anxious X IBDQ, IBDSI
 • tearful, upset X IBDQ, IBDQ-36, IBDSI
 • depressed X X CDPWDG, IBDQ,
IBDQ-36, IBDSI
 • irritable X IBDQ, IBDQ-36, IBDSI
 • angry X X IBDQ, IBDQ-36, IBDSI
 • mood swings X X
 • self-blame /guilt X X
 • hopelessness X IBDSI
Impaired cognitive functioning X IBDSI
aCDPWDG: Crohn’s Disease Perceived Work Disability Questionnaire34
IBDQ: Inflammatory Bowel Disease Questionnaire (32 items)6
IBDQ-36: Inflammatory Bowel Disease Questionnaire (36 items)33
IBDSI: Inflammatory Bowel Disease Stress Index8
RFIPC: Rating Form of IBD Patient Concerns7
WPAI-CD: Work Productivity and Activity Impairment Questionnaire: Crohn’s Disease35
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